share_log

Insider Buying: Aura Biosciences, Inc. (NASDAQ:AURA) Director Purchases $123,700.00 in Stock

Insider Buying: Aura Biosciences, Inc. (NASDAQ:AURA) Director Purchases $123,700.00 in Stock

內幕購買：靈氣生物科學股份有限公司（納斯達克：AURA）董事購買了 123,700.00 美元的股票
Defense World ·  2022/12/18 05:51

Aura Biosciences, Inc. (NASDAQ:AURA – Get Rating) Director David Michael Johnson bought 10,000 shares of Aura Biosciences stock in a transaction that occurred on Thursday, December 1st. The stock was bought at an average price of $12.37 per share, for a total transaction of $123,700.00. Following the completion of the acquisition, the director now directly owns 15,000 shares of the company's stock, valued at $185,550. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink.

奧拉生物科學公司(納斯達克代碼：AURA-GET評級)董事David邁克爾·約翰遜在12月1日星期四的一筆交易中購買了10,000股奧拉生物科學公司的股票。這只股票的平均價格為每股12.37美元，總成交額為123,700.00美元。收購完成後，董事現在直接擁有15,000股該公司股票，價值185,550美元。此次收購是在提交給美國證券交易委員會的一份法律檔案中披露的，該檔案可在以下網址獲得此超鏈接.

Aura Biosciences Trading Up 1.8 %

AURA生物科學公司股價上漲1.8%

Shares of AURA stock opened at $12.17 on Friday. The business's 50 day simple moving average is $12.96 and its 200 day simple moving average is $14.20. Aura Biosciences, Inc. has a one year low of $11.29 and a one year high of $24.83.

AURA股票週五開盤報12.17美元。該業務的50日簡單移動均線切入位為12.96美元，200日簡單移動均線切入位為14.20美元。Aura Biosciences，Inc.的一年低點為11.29美元，一年高位為24.83美元。

Get
到達
Aura Biosciences
奧拉生物科學
alerts:
警報：

Aura Biosciences (NASDAQ:AURA – Get Rating) last announced its earnings results on Thursday, November 10th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.52) by ($0.01). As a group, equities analysts anticipate that Aura Biosciences, Inc. will post -2.02 EPS for the current year.

奧拉生物科學(納斯達克：AURA-GET評級)最近一次公佈財報是在11月10日(週四)。該公司公佈本季度每股收益(0.53美元)，低於普遍預期的(0.52美元)和(0.01美元)。作為一個整體，股票分析師預計奧拉生物科學公司本年度每股收益將為2.02歐元。

Hedge Funds Weigh In On Aura Biosciences

對沖基金對Aura Bioscions的看法

Several institutional investors have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp lifted its stake in Aura Biosciences by 25.5% in the third quarter. Bank of New York Mellon Corp now owns 50,336 shares of the company's stock valued at $912,000 after buying an additional 10,240 shares during the period. BNP Paribas Arbitrage SNC acquired a new position in Aura Biosciences in the third quarter valued at approximately $105,000. State Street Corp lifted its stake in Aura Biosciences by 16.2% in the third quarter. State Street Corp now owns 298,438 shares of the company's stock valued at $5,408,000 after buying an additional 41,692 shares during the period. Vanguard Group Inc. lifted its stake in Aura Biosciences by 39.2% in the third quarter. Vanguard Group Inc. now owns 605,884 shares of the company's stock valued at $10,978,000 after buying an additional 170,709 shares during the period. Finally, BlackRock Inc. lifted its stake in Aura Biosciences by 14.3% in the third quarter. BlackRock Inc. now owns 1,013,455 shares of the company's stock valued at $18,363,000 after buying an additional 126,732 shares during the period. 53.96% of the stock is owned by institutional investors and hedge funds.
幾家機構投資者最近增持或減持了該公司的股份。紐約梅隆銀行(Bank Of New York Mellon Corp)在第三季度將其在Aura Biosciences的持股增加了25.5%。紐約梅隆銀行(Bank Of New York Mellon Corp)目前持有50,336股該公司股票，價值912,000美元，在此期間又購買了10,240股。法國巴黎銀行套利SNC在第三季度收購了Aura Biosciences的新頭寸，價值約為105,000美元。道富集團在第三季度增持了16.2%的Aura Biosciences股份。道富銀行目前持有298,438股該公司股票，價值5,408,000美元，在此期間又購買了41,692股。先鋒集團(Vanguard Group Inc.)在第三季度增持了Aura Biosciences 39.2%的股份。先鋒集團目前持有605,884股該公司股票，價值10,978,000美元，在此期間又購買了170,709股。最後，貝萊德股份有限公司在第三季度增持了14.3%的奧拉生物科技股份。貝萊德股份有限公司在此期間增持了126,732股，目前持有1,013,455股該公司股票，價值18,363,000美元。53.96%的股票由機構投資者和對沖基金持有。

Wall Street Analyst Weigh In

華爾街分析師也加入進來

Separately, JMP Securities upped their target price on Aura Biosciences from $26.00 to $30.00 and gave the company a "market outperform" rating in a report on Friday, November 11th.

另外，JMP證券在11月11日(星期五)的一份報告中將Aura Biosciences的目標價從26.00美元上調至30.00美元，並給予該公司“市場表現優於大盤”的評級。

About Aura Biosciences

關於奧拉生物科學公司

(Get Rating)

(獲取評級)

Aura Biosciences, Inc operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma.

Aura Biosciences，Inc.是一家開發癌症治療方法的生物技術公司。該公司開發病毒樣藥物結合物(VDC)技術平臺，用於治療眼科和泌尿外科腫瘤學中高度未得到滿足的腫瘤。它開發了AU-011，一種治療原發脈絡膜黑色素瘤的VDC候選藥物。

Featured Stories

專題報道

  • Get a free copy of the StockNews.com research report on Aura Biosciences (AURA)
  • MarketBeat: Week in Review 12/12 – 12/16
  • Which Two Bluechip Tech Companies Have Raised Their Guidance?
  • Should You Worry About Elon Musk Selling His Tesla Shares?
  • Can Tractor Supply Stock Surge Past Cup-With-Handle Buy Point?
  • This is no Time to Buy Lennar but the Time is Coming
  • 免費獲取StockNews.com關於AURA生物科學的研究報告(AURA)
  • MarketBeat：回顧一週12/12-12/16
  • 哪兩家藍籌科技公司提高了他們的指引？
  • 你應該擔心埃隆·馬斯克出售他持有的特斯拉股票嗎？
  • 拖拉機庫存能否突破杯柄收購點？
  • 現在不是購買Lennar的時候，但時機即將到來

Receive News & Ratings for Aura Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aura Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

接受《奧拉生物科學日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Aura Biosciences和相關公司的最新新聞和分析師評級的每日簡要摘要。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論